INDEGENE
|
INDEGENE Last 5 Year Financial Ratios History
[Consolidated]
| Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 15.17 | 12.01 | 938.81 | 954.66 | -40.26 |
| CEPS(Rs) | 18.59 | 14.71 | 8.88 | 10.71 | 3.47 |
| DPS(Rs) | - | - | - | - | - |
| Book NAV/Share(Rs) | 62.96 | 47.22 | 4,319.87 | 2,045.39 | -699.60 |
| Tax Rate(%) | 26.58 | 26.69 | 28.11 | 19.78 | 34.66 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 19.52 | 17.17 | 17.24 | 23.86 | 22.34 |
| EBIT Margin(%) | 19.62 | 17.10 | 13.96 | 24.67 | 13.08 |
| Pre Tax Margin(%) | 17.71 | 15.74 | 13.61 | 23.95 | 11.71 |
| PAT Margin (%) | 13.00 | 11.54 | 9.78 | 19.22 | 7.65 |
| Cash Profit Margin (%) | 15.94 | 14.13 | 11.79 | 21.86 | 10.65 |
| Performance Ratios | |||||
| ROA(%) | 14.60 | 15.56 | 17.66 | 33.13 | 11.08 |
| ROE(%) | 27.56 | 29.50 | 30.20 | 176.32 | - |
| ROCE(%) | 30.88 | 35.20 | 41.09 | 68.54 | 29.65 |
| Asset Turnover(x) | 1.12 | 1.35 | 1.81 | 1.72 | 1.45 |
| Sales/Fixed Asset(x) | 2.79 | 4.06 | 7.20 | 4.71 | 3.11 |
| Working Capital/Sales(x) | 2.19 | 2.40 | 2.41 | 3.72 | 3.76 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.36 | 0.25 | 0.14 | 0.21 | 0.32 |
| Receivable days | 90.91 | 85.94 | 79.96 | 87.03 | 75.45 |
| Inventory Days | - | - | - | - | - |
| Payable days | - | - | - | - | - |
| Valuation Parameters | |||||
| PER(x) | - | - | - | - | - |
| PCE(x) | - | - | - | - | - |
| Price/Book(x) | - | - | - | - | - |
| Yield(%) | - | - | - | - | - |
| EV/Net Sales(x) | 0.10 | 0.15 | -0.30 | -0.12 | 0.42 |
| EV/Core EBITDA(x) | 0.44 | 0.78 | -1.59 | -0.44 | 1.84 |
| EV/EBIT(x) | 0.50 | 0.89 | -2.15 | -0.48 | 3.22 |
| EV/CE(x) | 0.14 | 0.24 | -0.64 | -0.33 | 0.78 |
| M Cap / Sales | - | - | - | - | - |
| Growth Ratio | |||||
| Net Sales Growth(%) | 12.29 | 38.54 | 72.27 | 50.30 | 16.20 |
| Core EBITDA Growth(%) | 28.10 | 45.17 | 19.77 | 77.55 | 202.82 |
| EBIT Growth(%) | 28.84 | 69.62 | -2.50 | 183.49 | 163.05 |
| PAT Growth(%) | 26.53 | 63.43 | -12.31 | 277.40 | 249.16 |
| EPS Growth(%) | 26.25 | -98.72 | -1.66 | 2,471.51 | -144.74 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.29 | 0.38 | 0.02 | 0.08 | -4.12 |
| Current Ratio(x) | 2.93 | 2.96 | 2.57 | 2.30 | 1.69 |
| Quick Ratio(x) | 2.93 | 2.96 | 2.57 | 2.30 | 1.69 |
| Interest Cover(x) | 10.28 | 12.60 | 38.98 | 34.27 | 9.56 |
| Total Debt/Mcap(x) | - | - | - | - | - |
Compare Financial Ratios of peers of INDEGENE
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| INDEGENE | ₹13,346.4 Cr | -3.8% | 5.3% | NA | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹410,142.0 Cr | -1.5% | 9.1% | 9.1% | Stock Analytics | |
| DIVIS LABORATORIES | ₹145,762.0 Cr | -4.9% | -0.6% | 59.1% | Stock Analytics | |
| CIPLA | ₹114,322.0 Cr | -1.8% | 1% | 0.5% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹111,171.0 Cr | 1.6% | 12.1% | 21.8% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹92,603.7 Cr | -3% | -0.9% | -7.7% | Stock Analytics | |
INDEGENE Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| INDEGENE | -3.8% |
5.3% |
|
| SENSEX | -2.9% |
3.1% |
1.8% |
You may also like the below Video Courses
